Copiamycin, a macrocyclic lactone antifungal antibiotic, was found to potentiate the antifungal effect of imidazole compounds, ketoconazole in particular. The potentiation of two nominally fungistatic agents in vitro was substantiated by a marked reduction of the minimum inhibitory and minimum fungicidal concentrations when the drugs were used in combination. The effectiveness of this synergistic combination was also demonstrated in experimental murine candidosis. Evidence is presented to suggest that this combined effect is due, at least in part, to the ionophoretic property of copiamycin. Whereas amphotericin B induces a marked increase in cellular permeability, this antibiotic does not possess the ionophoretic action of copiamycin, indicating that the enhancement of copiamycin activity and significant reduction of amphotericin B activity by ketoconazole pretreatment can be ascribed not only to changes in membrane permeability of the test organisms, but also to the different action mechanisms of copiamycin and amphotericin B. It is thus plausible that the strong synergism of copiamycin with imidazole compounds is related to the ionophoretic activity of the antibiotic. Further studies on the biochemical mechanism of this synergistic effect are being conducted together with an assessment of the clinical significance of this drug combination.
Among the various infectious diseases, the chemotherapy for systemic fungal infections in patients, particularly those with impaired host defense mechanisms, has been most discouraging. Until recently, amphotericin B was the only chemotherapeutic agent available for use against these infections. Recently, 5-fluorocytosine was developed and shown to be effective against candidosis and cryptococcosis. However, the major defect of 5-fluorocytosine therapy is the rapid development of organisms resistant to this antimycotic. In addition, the compound is primarily fungistatic. More recently, a number of chlorinated imidazole compounds have been found to have antifungal as well as antibacterial activity. Among them, clotrimazole, miconazole, and econazole have already been used in topical and in some cases systemic therapy.
Ketoconazole is a newer dioxolane imidazole which shows promise as a broad-spectrum antifungal agent effective by oral administration. In our studies on the mode of action of ketoconazole (24, 25, 27) , we demonstrated that the mechanism of action of this compound is somewhat different from those of the other imidazole antifungal agents. Our results indicated that the primary site of action of ketoconazole is cytochrome c oxidase (25) . On the other hand, Van den Bossche et al. reported that ketoconazole had an effect on cytochrome P-450 with subsequent inhibition of sterol biosynthesis (28, 29) .
Although preliminary clinical studies seem to indicate the potential usefulness of this drug for the treatment of systemic mycoses, its mode of action seems to be more fungistatic rather than fungicidal at clinically achievable concentrations.
On the other hand, potential antifungal chemotherapeutics must be fungicidal or cause a marked reduction in viability to be effective on opportunistic fungal infections, because the patient's defense mechanisms are usually markedly impaired in these cases. Therefore, to provide safer and more effective antifungal treatment, newer protocol concepts must be developed. One method has been to use combination therapy of amphotericin B with other antimicrobial agents or an intermediate of sterol biosynthesis (19) . Others have used two different antimycotics (3) .
Antifungal activity of preferentially antibacterial antibiotics when combined with amphotericin B was first described by Kwan et al. in 1972 (16) . This kind of potentiation of amphotericin B was also observed with tetracycline (14) , minocycline (12, 17) , rifampin (2, 9) , bleomycin, and (7, 26) .
Copiamycin is an antifungal antibiotic isolated by Arai et al. in 1965 (1) . This antibiotic is slightly soluble in water and mostly fungistatic even at a high concentration; it was not studied in detail. The skeletal structure of copiamycin was elucidated recently (10) , and the antibiotic was found to belong to the macrocyclic lactone antibiotics such as polyene macrolides. However, it does not possess a conjugated double-bond structure, as do polyenes.
The macrocyclic lactone structure of copiamycin suggested that the antibiotic might interfere with the activity of imidazole compounds as amphotericin B does. In striking contrast, the combination proved to be strongly synergistic in vitro as well as in vivo.
MATERIALS AND METHODS Chemicals. Copiamycin was produced by fermentation of Streptomyces hygroscopicus subsp. crystallogenes as described by Arai et 
RESULTS
The skeletal structure of copiamycin (10) is compared with that of amphotericin B in Fig. 1 . Copiamycin consists of a 32-membered polyhydroxy lactone ring and an unsaturated ester group, as well as a side chain with a disubstituted guanidine moiety as its terminal. Table 1 shows the antifungal spectrum of copiamycin. It is interesting to note that Geotricum candidum, which is reported to be resistant to known imidazole compounds (8) , is susceptible to this antibiotic. Pathogenic yeasts such as some strains of C. albicans and Candida stellatoidea were less susceptible, being inhibited at the concentration of 50 ,ug/ml. The combination of ketoconazole and amphotericin B seemed to be mostly antagonistic as revealed by a constriction of the inhibition zone (Fig. 2) . In contrast, the combination of copiamycin and ketoconazole was evidently synergistic. The combined effect of ketoconazole and clotrimazole was not significant under the present experimental conditions. higher than those of clotrimazole, miconazole, and econazole. The highest synergism was obtained with the combination of copiamycin and ketoconazole at the ratio of 4:1, followed by 1:1 and 1:4. Synergism was also observed with the combination of copiamycin and other imidazole compounds, although less significantly than with ketoconazole. Again, the highest potentiation 4Ĩ a was obtained with copiamycin and these imidazole compounds in the combination ratio of 4:1. Figure 3 The effect of copiamycin on the rate of respiration of mitochondria from rat liver was comtag/ml. However, all the test strains were inhibit-pared to those of valinomycin, amphotericin B, ed when 0.2 F.g of copiamycin per ml was added. and antimycin A (Fig. 5) . Similar studies were
The case was similar when 6.23 ,ug of ketocona-made of the effect of copiamycin on atitochonzole per ml and 0.78 ,g of copiamycin per ml dria light scattering and on K+ and H' movewere used in combination. Even -the combina-ments (Fig. 6) . In a medium containing K+, tion of ketoconazole and copiamycin at concen-copiamycin and valinomycin significantly stimutrations far below their respective MICs, i.e., lated,respiration, whereas amphoto cn B ex-0.78 ,g of copiamycin and 1.56 pg of ketocona-hibited entirely no effect and, by contrast, antizole per ml, was found to be highly active, mycin A caused immediate cessation of suppressing the growth of all the test strains.
respiration. The stimulation of respiration withIn our preceding experiments with ketocona-out ADP presents direct evidence of the uncouzole (27), we noted an unusually wide range of plingaffect of copiamycin. Rapid rekase of K+ MIC and maximum growth allowance concen-was observed immediately after the addition of tration. The same feature of antibiotic activity copiamycin (ig. 6). Mitochon4rial swelling, as ws observed withcopiamycin against T. menta-monitored by light scattering at 540 nm, was also grophytes in particular. These experimental re-observed :in prallel with this K+ exit. On the sults indicated that both drugs are mostly fungis-other hand, the uptake of H+ frosi the medium tatic rather than fungicidal. However, the wps revealed by an increase in pH. In a preliminary attempt to analyze the mechanism involved in the synergistic (ketoconazolecopiamycin) or antagonistic (ketoconazole-amphotericin B) effect, the effectiveness of these antimycotics alone or in combination on the growth rate of C. albicans was studied (Fig. 7) . When sub-inhibitory doses of ketoconazole were added to cultures growing for 12 h in the presence of a sub-inhibitory concentration of copiamycin, little growth retardation of the test organism was observed. On the other hand, when copiamycin was added to cultures pretreated with ketoconazole, an instantaneous lethal effect took place (Fig. 7A) cidal doses of amphotericin B, added to the culture containing a sub-inhibitory dose of ketoconazole, failed to cause significant growth retardation (Fig. 7C) . In this case, antagonism between ketoconazole and amphotericin B was evident. DISCUSSION In our studies on the mode of action of 5-fluorocytosine (31) and ketoconazole (24, 25, 27) , we showed evidence that these two drugs have one character in common, i.e., they are predominantly fungistatic at clinically achievable levels as compared to those more toxic known antifungal agents.
5-Fluorocytosine is a novel antimycotic with minimal toxicity. The sophisticated mechanism of the selective toxicity of 5-fluorocytosine to yeasts is explained by its selective incorporation into yeast cells (31) . However, the inhibitory effect of the compound against a variety offungi is not complete in common complex organic media.
Ketoconazole is unusual in that it is orally active and has much better chemotherapeutic use due to a lower toxicity than already known imidazole derivatives.
These facts seem to suggest that more beneficial antifungal chemotherapeutics can be found among the compounds which have an extraordinarily wide fungistatic concentration range.
However, fungicidal rather than fungistatic chemotherapeutics are required to cope particularly with opportunistic infections in patients with impaired host defense mechanisms. Therefore, the present studies were undertaken in a bid to solve this contradictory problem by combination therapy. Copiamycin, a macrocyclic lactone antifungal antibiotic, in combination with imidazole antifungal agents exhibited marked synergism in vitro and in vivo. The assessment of the combined effect of antifungal agents in vitro and in vivo is sometimes difficult, and conflicting reports have been published, as in the case of the combination of amphotericin B with imidazole antifungal agents. With copiamycin plus imidazole antifungal agents, the potentiation of antifungal activity was 50-to 100-fold with regard to the respective MICs; these results were unequivocal. This augmented potency was further substantiated by the fact that the combination became fungicidal, unlike when each drug was exerted alone.
At first sight of the structure of copiamycin, whose backbone is capable of assuming a conformation that focuses the oxygens about a ring or cavity in space to complex various cations, one may infer an ionophoretic activity of the antibiotic (23 (11) , and other ionophore antibiotics (5, 6, 23, 30) .
